Taken together, these results indicated that PLGA nanoparticles were successful in the delivery of siRNA therapeutics and knockdown of the MAPK6 with siMAPK6‐PLGA‐NPs led to significant anticancer effects against MCF‐7 BC cells. Here, MAPK6 is linked to breast cancer.